What is Clene Nanomedicine?
Clene Nanomedicine specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company's flagship candidate, CNM-Au8, is currently undergoing extensive clinical investigation for its potential efficacy in treating amyotrophic lateral sclerosis (ALS), Parkinson's disease, and chronic optic neuropathy. Beyond its neurological focus, the firm is diversifying its portfolio with CNM-AgZn17 and CNM-ZnAg, which target infectious diseases and provide immune support through advanced silver and zinc ion delivery systems. This multi-faceted approach to drug development distinguishes Clene within the competitive biotechnology sector, as it seeks to translate complex nanotechnology into scalable, patient-centric medical solutions.
How much funding has Clene Nanomedicine raised?
Clene Nanomedicine has raised a total of $140.3M across 7 funding rounds:
Series A
$31.6M
Series B
$17M
Debt
$350K
Series D
$42.5M
Other Financing Round
$40M
Other Financing Round
$7.3M
Stock/Share Issuance
$1.5M
Series A (2015): $31.6M, investors not publicly disclosed
Series B (2016): $17M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $42.5M featuring SymBiosis II
Other Financing Round (2023): $40M backed by Vivo Capital, Acuta Capital Partners, and Symbiosis Group
Other Financing Round (2024): $7.3M, investors not publicly disclosed
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Key Investors in Clene Nanomedicine
Vivo Capital
Vivo Capital is a global healthcare investment firm founded in 1996, specializing in private and public equity as well as venture capital to support medical innovation.
Acuta Capital Partners
Acuta Capital Partners is a California-based financial group dedicated to supporting healthcare companies that aim to enhance health outcomes through research and innovation.
Symbiosis Group
Symbiosis Group is an organization focused on the dissemination of scientific research through international open-access journals and scholarly publications.
What's next for Clene Nanomedicine?
With the recent capital deployment, Clene Nanomedicine is well-positioned to accelerate its Phase 2 and potential Phase 3 clinical trial programs. The strategic focus remains on validating the safety and efficacy of its lead candidates while optimizing the manufacturing processes for its CSN platform. Investors are closely monitoring the company's progress in ALS and Parkinson's research, as positive data readouts could significantly enhance the firm's valuation and market reach. Moving forward, the company is expected to prioritize regulatory engagement and potential commercialization partnerships to ensure its innovative therapies reach the clinical market efficiently, thereby solidifying its long-term growth trajectory in the global pharmaceutical industry.
See full Clene Nanomedicine company page
